

Carsten Nieder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7943397/publications.pdf>

Version: 2024-02-01

280
papers

6,420
citations

81900

39
h-index

95266

68
g-index

309
all docs

309
docs citations

309
times ranked

5831
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary systemic therapy for patients with brain metastases from lung cancer ineligible for targeted agents. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	2.5	1
2	A Case of Five-Year Survival After Combined-Modality Treatment for Non-Small Cell Lung Cancer With Intraspinal Metastasis. <i>Cureus</i> , 2022, 14, e20960.	0.5	0
3	Dual Use of the METSSS Model Predicting Survival After Palliative Radiotherapy: An Exploratory Analysis. <i>Cureus</i> , 2022, 14, e21223.	0.5	0
4	Implementation of Locoregional Adjuvant Radiotherapy for Breast Cancer in a Rural Healthcare Region: Toxicity Outcomes in the Initial Cohort. <i>Anticancer Research</i> , 2022, 42, 923-928.	1.1	0
5	Shortened Palliative Radiotherapy Results in a Lower Rate of Treatment During the Last Month of Life. <i>Cureus</i> , 2022, 14, e21617.	0.5	0
6	Established Serum Biomarkers Are Prognostic Factors in Patients With Oligometastatic Cancer and Brain Involvement. <i>In Vivo</i> , 2022, 36, 801-805.	1.3	4
7	Independent External Validation of the METSSS Model Predicting Survival After Palliative Radiotherapy. <i>Anticancer Research</i> , 2022, 42, 1477-1480.	1.1	3
8	Feasibility and efficacy of early docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in a rural health care setting. <i>Scandinavian Journal of Urology</i> , 2022, 56, 114-118.	1.0	2
9	Palliative non-small cell lung cancer treatment and end-of-life care stratified by sex and childlessness: an important interplay in unmarried patients?. <i>Supportive Care in Cancer</i> , 2022, , 1.	2.2	0
10	30-day mortality in patients treated for brain metastases: extracranial causes dominate. <i>Radiation Oncology</i> , 2022, 17, 92.	2.7	6
11	Neurological Death After Radiotherapy for Brain Metastases: Role of the LabBM Score. <i>Anticancer Research</i> , 2021, 41, 341-345.	1.1	1
12	Palliative Thoracic Radiotherapy for Non-Small Cell Lung Cancer in Outpatients: Reasons for Unplanned Hospitalization and Its Impact on Survival. <i>Journal of Clinical Medicine Research</i> , 2021, 13, 177-183.	1.2	0
13	An Institutional Audit of Maximum Heart Dose in Patients Treated With Palliative Radiotherapy for Non-small Cell Lung Cancer. <i>In Vivo</i> , 2021, 35, 955-958.	1.3	0
14	Recursive Partitioning Analysis of Systemic Therapy after Radiotherapy in Patients with Brain Metastases. <i>Oncology Research and Treatment</i> , 2021, 44, 1-6.	1.2	4
15	Validation of a Graded Prognostic Model in Patients With Brain Metastases Treated With Whole-brain Radiotherapy Instead of Radiosurgery. <i>In Vivo</i> , 2021, 35, 1569-1572.	1.3	0
16	Radiate Once More. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 314-315.	0.8	0
17	Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases. <i>Anticancer Research</i> , 2021, 41, 1471-1474.	1.1	10
18	Symptom Burden in Patients Treated With Palliative Radiotherapy Before and During the COVID-19 Pandemic. <i>Anticancer Research</i> , 2021, 41, 1971-1974.	1.1	4

#	ARTICLE	IF	CITATIONS
19	New clinical data on human spinal cord re-irradiation tolerance. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 463-473.	2.0	10
20	In Regard to Alcorn et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 612-614.	0.8	2
21	Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models?. <i>Radiotherapy and Oncology</i> , 2021, 159, 17-20.	0.6	7
22	Hippocampus-Avoidance Whole-Brain Radiation Therapy Is Efficient in the Long-Term Preservation of Hippocampal Volume. <i>Frontiers in Oncology</i> , 2021, 11, 714709.	2.8	11
23	The LabBM score is an excellent survival prediction tool in patients undergoing palliative radiotherapy. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 740-746.	0.6	8
24	Early High-Grade Thoracic Toxicity After Palliative Radiotherapy for Non-Small Cell Lung Cancer. <i>Cureus</i> , 2021, 13, e12494.	0.5	2
25	Palliative Radiotherapy During the Last Month of Life: Have COVID-19 Recommendations Led to Reduced Utilization?. <i>In Vivo</i> , 2021, 35, 649-652.	1.3	10
26	Palliative Thoracic Radiotherapy for Non-small Cell Lung Cancer: Is There any Impact of Target Volume Size on Survival?. <i>Anticancer Research</i> , 2021, 41, 355-358.	1.1	4
27	Expansion of the LabBM Score. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 53-57.	1.3	5
28	Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer. <i>Radiation Oncology</i> , 2020, 15, 91.	2.7	6
29	Radiotherapy for nonagenarians: the value of biological versus chronological age. <i>Radiation Oncology</i> , 2020, 15, 113.	2.7	12
30	Altered fractionation short-course radiotherapy for stage II-III rectal cancer: a retrospective study. <i>Radiation Oncology</i> , 2020, 15, 111.	2.7	1
31	Long-term survival results after treatment for oligometastatic brain disease. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 307-311.	0.6	9
32	External Validation of a Prognostic Score for Patients with Brain Metastases: Extended Diagnosis-Specific Graded Prognostic Assessment. <i>Oncology Research and Treatment</i> , 2020, 43, 221-227.	1.2	8
33	Hippocampus-avoidance whole-brain radiation therapy with a simultaneous integrated boost for multiple brain metastases. <i>Cancer</i> , 2020, 126, 2694-2703.	4.1	41
34	Feasibility and efficacy of sequential systemic therapy for metastatic castration-resistant prostate cancer in a rural health care setting. <i>Scandinavian Journal of Urology</i> , 2020, 54, 110-114.	1.0	1
35	Confirmatory Analysis of QUARTZ Study Results: Survival Prolongation After Whole-brain Radiotherapy. <i>Anticancer Research</i> , 2020, 40, 977-981.	1.1	3
36	Management of Patients With Metastatic Renal Cell Cancer and Bone Metastases. <i>In Vivo</i> , 2020, 34, 675-678.	1.3	3

#	ARTICLE	IF	CITATIONS
37	Symptom Burden in Patients With Reduced Performance Status at the Start of Palliative Radiotherapy. <i>In Vivo</i> , 2020, 34, 735-738.	1.3	3
38	Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA). <i>Radiation Oncology</i> , 2020, 15, 35.	2.7	6
39	Is there a seasonal variation of survival after systemic chemotherapy for metastatic castration-resistant prostate cancer in a rural part of North Norway?. <i>International Journal of Circumpolar Health</i> , 2020, 79, 1742520.	1.2	0
40	Symptom Burden in Patients With Oligometastases at the Start of Palliative Radiotherapy. <i>Anticancer Research</i> , 2020, 40, 1551-1554.	1.1	0
41	Provider decision regretâ€”a Useful method for analysis of palliative thoracic re-irradiation for lung cancer?. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 315-324.	2.0	5
42	Initial Experience after Transition to Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer Treated in a Rural Healthcare Region. <i>Cureus</i> , 2020, 12, e7030.	0.5	5
43	LabBM Score and Extracranial Score As New Tools for Predicting Survival in Patients with Brain Metastases Treated with Focal Radiotherapy. <i>Cureus</i> , 2020, 12, e7633.	0.5	0
44	Late Brain Oligometastases Diagnosed at Least 36 Months after Cancer Detection are Associated with Favorable Survival Outcome. <i>Cureus</i> , 2020, 12, e6553.	0.5	2
45	Independent External Validation of a Score Predicting Survival After Radiotherapy for Bone Metastases and Expansion to Patients Treated With Single Fraction Radiotherapy. <i>Journal of Clinical Medicine Research</i> , 2020, 12, 90-99.	1.2	2
46	Risk Factors for Local Relapse and Inferior Disease-free Survival After Breast-conserving Management of Breast Cancer: Recursive Partitioning Analysis of 2161 Patients. <i>Clinical Breast Cancer</i> , 2019, 19, 58-62.	2.4	9
47	Management of patients with metastatic prostate cancer (mPC) in a rural part of North Norway with a scattered population: does living near the department of oncology translate into a different pattern of care and survival?. <i>International Journal of Circumpolar Health</i> , 2019, 78, 1620086.	1.2	6
48	Definitive, intensity modulated tomotherapy with a simultaneous integrated boost for prostate cancer patients â€” Long term data on toxicity and biochemical control. <i>Reports of Practical Oncology and Radiotherapy</i> , 2019, 24, 315-321.	0.6	4
49	External validation of a prognostic score predicting overall survival for patients with brain metastases based on extracranial factors. <i>Clinical and Translational Radiation Oncology</i> , 2019, 16, 15-20.	1.7	8
50	Serum Lactate Dehydrogenase Contributes to Prognostic Assessment in Patients With Oligometastatic Cancer and Brain Involvement. <i>In Vivo</i> , 2019, 33, 229-232.	1.3	7
51	Contribution of Serum Biomarkers to Prognostic Assessment in Patients With Oligometastatic Prostate Cancer. <i>In Vivo</i> , 2019, 33, 465-468.	1.3	4
52	Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous. <i>Radiation Oncology</i> , 2019, 14, 33.	2.7	24
53	Contribution of adverse events to death of hospitalised patients. <i>BMJ Open Quality</i> , 2019, 8, e000377.	1.1	18
54	Diffusion-weighted MRI and ADC versus FET-PET and Gd1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma. <i>Radiotherapy and Oncology</i> , 2019, 130, 121-131.	0.6	24

#	ARTICLE	IF	CITATIONS
55	Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2019, 129, 63-71.	2.0	25
56	Initiation of Systemic Therapy During the Last 30 Days of Life in Patients With Metastatic Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2019, 39, 335-340.	1.1	3
57	Patterns of Treatment and Outcome in Patients With 20 or More Brain Metastases. <i>In Vivo</i> , 2019, 33, 173-176.	1.3	3
58	Second re-irradiation: A delicate balance between safety and efficacy. <i>Physica Medica</i> , 2019, 58, 155-158.	0.7	7
59	External Validation of the LabBM Score in Patients With Brain Metastases. <i>Journal of Clinical Medicine Research</i> , 2019, 11, 321-325.	1.2	15
60	Presence of Brain Metastases at Initial Diagnosis of Cancer: Patient Characteristics and Outcome. <i>Cureus</i> , 2019, 11, e4113.	0.5	11
61	Seven-month prostate-specific antigen (PSA) is prognostic in patients with prostate cancer initially diagnosed with distant metastases. <i>Medical Oncology</i> , 2018, 35, 46.	2.5	3
62	Radiation Therapy in Brain Metastasis of Solid Tumors: A Challenge for the Future. , 2018, , 1-16.		0
63	Patient-reported symptoms before palliative radiotherapy predict survival differences. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 533-538.	2.0	10
64	Repeat reirradiation of the spinal cord: multi-national expert treatment recommendations. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 365-374.	2.0	17
65	A Four-Tiered Prognostic Score for Patients Receiving Palliative Thoracic Radiotherapy for Lung Cancer. <i>Cancer Investigation</i> , 2018, 36, 59-65.	1.3	5
66	Prognostic and predictive factors in patients with brain metastases from solid tumors: A review of published nomograms. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 13-18.	4.4	51
67	Second re-irradiation: a narrative review of the available clinical data. <i>Acta OncolÃ³gica</i> , 2018, 57, 305-310.	1.8	16
68	Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature. <i>ESMO Open</i> , 2018, 3, e000406.	4.5	84
69	Local control and possibility of tailored salvage after hypofractionated stereotactic radiotherapy of the cavity after brain metastases resection. <i>Cancer Medicine</i> , 2018, 7, 2350-2359.	2.8	15
70	Validation of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). <i>Journal of Clinical Medicine Research</i> , 2018, 10, 178-181.	1.2	11
71	Does Marital Status Influence Levels of Anxiety and Depression Before Palliative Radiotherapy?. <i>In Vivo</i> , 2018, 32, 327-330.	1.3	9
72	Second Re-irradiation of Brain Metastases: A Review of Studies Involving Stereotactic Radiosurgery. <i>Cureus</i> , 2018, 10, e3712.	0.5	7

#	ARTICLE	IF	CITATIONS
73	Frequency and Prognostic Impact of Consistently Low Edmonton Symptom Assessment System Score in the Patients Treated with Palliative Radiotherapy. <i>Cureus</i> , 2018, 10, e2032.	0.5	1
74	Does Patient-reported Dyspnea Reflect Thoracic Disease Characteristics in Patients with Incurable Cancer?. <i>Anticancer Research</i> , 2018, 38, 901-904.	1.1	4
75	How Should Palliative Thoracic Radiotherapy Be Fractionated for Octogenarians with Lung Cancer?. <i>In Vivo</i> , 2018, 32, 331-336.	1.3	2
76	Patient-reported Symptom Burden, Rate of Completion of Palliative Radiotherapy and 30-day Mortality in Two Groups of Cancer Patients Managed With or Without Additional Care by a Multidisciplinary Palliative Care Team. <i>Anticancer Research</i> , 2018, 38, 2271-2275.	1.1	7
77	Contribution of Patient-reported Symptoms Before Palliative Radiotherapy to Development of Multivariable Prognostic Models. <i>Anticancer Research</i> , 2018, 38, 1705-1709.	1.1	3
78	Levels of Anxiety and Depression Before Palliative Reirradiation Are Comparable to Those Before First Palliative Radiotherapy. <i>Cureus</i> , 2018, 10, e2519.	0.5	0
79	Second Re-irradiation: Clinical Examples of Worthwhile Treatment. <i>Cureus</i> , 2018, 10, e2813.	0.5	1
80	External Validation of a Prognostic Score for Patients Receiving Palliative Thoracic Radiotherapy for Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, e297-e301.	2.6	9
81	Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 515-524.	2.0	13
82	The Glasgow prognostic score: Useful information when prescribing palliative radiotherapy. <i>Molecular and Clinical Oncology</i> , 2017, 6, 811-816.	1.0	3
83	Preserving the legacy of reirradiation: A narrative review of historical publications. <i>Advances in Radiation Oncology</i> , 2017, 2, 176-182.	1.2	16
84	Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians). <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2017, 1, 8-12.	1.9	6
85	Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region. <i>Medical Oncology</i> , 2017, 34, 149.	2.5	8
86	Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence. <i>Pharmacoeconomics</i> , 2017, 35, 1223-1236.	3.3	42
87	Adverse events in hospitalised cancer patients: a comparison to a general hospital population. <i>Acta Oncologica</i> , 2017, 56, 1218-1223.	1.8	27
88	Contemporary radiooncological management of bone metastases from breast cancer: factors associated with prescription of different fractionation regimens (short or long course) in a rural part of North Norway with long travel distance. <i>International Journal of Circumpolar Health</i> , 2017, 76, 1270080.	1.2	6
89	Local control and overall survival after frameless radiosurgery: A single center experience. <i>Clinical and Translational Radiation Oncology</i> , 2017, 7, 55-61.	1.7	19
90	Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA). <i>Radiation Oncology</i> , 2017, 12, 107.	2.7	35

#	ARTICLE	IF	CITATIONS
91	Expert consensus on re-irradiation for recurrent glioma. <i>Radiation Oncology</i> , 2017, 12, 194.	2.7	32
92	Palliative Thoracic Radiotherapy for Lung Cancer: What Is the Impact of Total Radiation Dose on Survival?. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 482-487.	1.2	22
93	Short Survival Time after Palliative whole Brain Radiotherapy: Can We Predict Potential Overtreatment by Use of a Nomogram?. <i>Journal of Cancer</i> , 2017, 8, 1525-1529.	2.5	11
94	Prognostic Impact of the Tumor Marker CA 15-3 in Patients With Breast Cancer and Bone Metastases Treated With Palliative Radiotherapy. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 183-187.	1.2	10
95	Polypharmacy in Older Patients ≥70 Years Receiving Palliative Radiotherapy. <i>Anticancer Research</i> , 2017, 37, 795-800.	1.1	15
96	Exceptional Responses to Standard Therapy in a Patient with Metastatic HER2-Positive Breast Cancer. <i>Cureus</i> , 2017, 9, e1412.	0.5	1
97	A Three-Variable Model Predicts Short Survival in Patients With Newly Diagnosed Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 281-288.	1.2	0
98	Survival and Symptom Relief after Palliative Radiotherapy for Esophageal Cancer. <i>Journal of Cancer</i> , 2016, 7, 125-130.	2.5	31
99	Impact of early palliative interventions on the outcomes of care for patients with non-small cell lung cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 4385-4391.	2.2	35
100	Fractionation Concepts. <i>Medical Radiology</i> , 2016, , 17-34.	0.1	1
101	Impact of intense systemic therapy and improved survival on the use of palliative radiotherapy in patients with bone metastases from prostate cancer. <i>Oncology Letters</i> , 2016, 12, 2930-2935.	1.8	10
102	Extracranial oral cavity metastasis from glioblastoma multiforme: A case report. <i>Molecular and Clinical Oncology</i> , 2016, 5, 437-439.	1.0	6
103	Normal Tissue Tolerance to Reirradiation. <i>Medical Radiology</i> , 2016, , 1-15.	0.1	0
104	Brain Metastases. <i>Medical Radiology</i> , 2016, , 337-356.	0.1	0
105	Prospective randomized clinical studies involving reirradiation. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 679-686.	2.0	16
106	Stereotactic fractionated radiotherapy of the resection cavity in patients with one to three brain metastases. <i>Clinical Neurology and Neurosurgery</i> , 2016, 142, 81-86.	1.4	21
107	Continuous prostate-specific antigen rise despite salvage radiotherapy following radical prostatectomy: Pattern of clinical relapse and predictive factors. <i>Oncology Letters</i> , 2016, 11, 1138-1142.	1.8	1
108	Predicted survival in patients with brain metastases from colorectal cancer: Is a current nomogram helpful?. <i>Clinical Neurology and Neurosurgery</i> , 2016, 143, 107-110.	1.4	15

#	ARTICLE	IF	CITATIONS
109	Re-irradiation for Recurrent Primary Brain Tumors. <i>Anticancer Research</i> , 2016, 36, 4985-4996.	1.1	47
110	Survival After Palliative Radiotherapy in Patients with Breast Cancer and Bone-only Metastases. <i>In Vivo</i> , 2016, 30, 879-884.	1.3	13
111	Treatment Results of MammoSite Catheter in Combination with Whole-breast Irradiation. <i>Anticancer Research</i> , 2016, 36, 355-60.	1.1	5
112	Palliative Radiotherapy in Cancer Patients with Increased Serum C-Reactive Protein Level. <i>In Vivo</i> , 2016, 30, 581-6.	1.3	9
113	Palliative radiotherapy during the last month of life: Predictability for referring physicians and radiation oncologists. <i>Oncology Letters</i> , 2015, 10, 3043-3049.	1.8	19
114	Undesirable financial effects of head and neck cancer radiotherapy during the initial treatment period. <i>International Journal of Circumpolar Health</i> , 2015, 74, 26686.	1.2	16
115	Stereotactic radiation therapy for liver metastases: factors affecting local control and survival. <i>Radiation Oncology</i> , 2015, 10, 69.	2.7	49
116	The challenge of durable brain control in patients with brain-only metastases from breast cancer. <i>SpringerPlus</i> , 2015, 4, 585.	1.2	11
117	Nontargeted Effect after Radiotherapy in a Patient with Non-Small Cell Lung Cancer and Bullous Pemphigoid. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-4.	0.3	4
118	Early palliative radiation therapy in patients with newly diagnosed cancer: Reasons, clinical practice, and survival. <i>Practical Radiation Oncology</i> , 2015, 5, e537-e542.	2.1	11
119	Palliative radiotherapy (PRT) during the last month of life: A constant sorrow even in a dedicated PRT facility with research focus on this endpoint. <i>Radiotherapy and Oncology</i> , 2015, 115, 284.	0.6	3
120	Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 461-469.	2.0	77
121	Palliative radiotherapy with or without additional care by a multidisciplinary palliative care team in patients with newly diagnosed cancer: a retrospective matched pairs comparison. <i>Radiation Oncology</i> , 2015, 10, 61.	2.7	12
122	Scientific impact of studies published in temporarily available radiation oncology journals: a citation analysis. <i>SpringerPlus</i> , 2015, 4, 93.	1.2	0
123	Tumor marker analyses in patients with brain metastases: patterns of practice and implications for survival prediction research. <i>Tumor Biology</i> , 2015, 36, 6471-6476.	1.8	8
124	PET-CT in the sub-arctic region of Norway 2010–2013. At the edge of what is possible?. <i>BMC Medical Imaging</i> , 2015, 15, 36.	2.7	6
125	A pooled analysis of stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small cell lung cancer: is failure to recruit patients into randomized trials also an answer to the research question?. <i>Annals of Translational Medicine</i> , 2015, 3, 148.	1.7	3
126	Development of a Score Predicting Survival after Palliative Reirradiation. <i>Journal of Oncology</i> , 2014, 2014, 1-7.	1.3	6

#	ARTICLE	IF	CITATIONS
127	Palliative Radiotherapy with or without Additional Care by a Multidisciplinary Palliative Care Team: A Retrospective Comparison. <i>ISRN Oncology</i> , 2014, 2014, 1-6.	2.1	2
128	A Case of Recurrent Breast Cancer with Solitary Metastasis to the Urinary Bladder. <i>Case Reports in Oncological Medicine</i> , 2014, 2014, 1-3.	0.3	5
129	Oligometastatic Non-Small Cell Lung Cancer: A Significant Entity outside of Specialized Cancer Centers?. <i>Medical Principles and Practice</i> , 2014, 23, 526-531.	2.4	28
130	Survival Prediction Score: A Simple but Age-Dependent Method Predicting Prognosis in Patients Undergoing Palliative Radiotherapy. <i>ISRN Oncology</i> , 2014, 2014, 1-5.	2.1	15
131	Impact of comorbidity on survival after palliative radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 1149-1153.	2.0	9
132	Stereotactic radiosurgery (SRS) for brain metastases: a systematic review. <i>Radiation Oncology</i> , 2014, 9, 155.	2.7	129
133	Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases. <i>Medical Oncology</i> , 2014, 31, 927.	2.5	14
134	Repeat palliative radiotherapy for painful bone metastases. <i>Lancet Oncology</i> , The, 2014, 15, 126-128.	10.7	2
135	Normal tissue studies in radiation oncology: A systematic review of highly cited articles and citation patterns. <i>Oncology Letters</i> , 2014, 8, 972-976.	1.8	3
136	Development and validation of a model predicting short survival (death within 30 days) after palliative radiotherapy. <i>Anticancer Research</i> , 2014, 34, 877-85.	1.1	18
137	Active anticancer treatment during the final month of life in patients with non-small cell lung cancer. <i>Anticancer Research</i> , 2014, 34, 1015-20.	1.1	14
138	Survival after palliative radiotherapy in geriatric cancer patients. <i>Anticancer Research</i> , 2014, 34, 6641-5.	1.1	11
139	Association between radiation dose and pathological complete response after preoperative radiochemotherapy in esophageal squamous cell cancer. <i>Anticancer Research</i> , 2014, 34, 7255-61.	1.1	9
140	Re-irradiation. , 2013, , 739-748.		0
141	Continuous controversy about radiation oncologists' choice of treatment regimens for bone metastases: should we blame doctors, cancer-related features, or design of previous clinical studies?. <i>Radiation Oncology</i> , 2013, 8, 85.	2.7	29
142	Radioimmunotherapy (RIT). , 2013, , 729-729.		0
143	Best supportive care in patients with brain metastases and adverse prognostic factors: development of improved decision aids. <i>Supportive Care in Cancer</i> , 2013, 21, 2671-2678.	2.2	22
144	Correlation between article download and citation figures for highly accessed articles from five open access oncology journals. <i>SpringerPlus</i> , 2013, 2, 261.	1.2	24

#	ARTICLE	IF	CITATIONS
145	Radiotherapy versus best supportive care in patients with brain metastases and adverse prognostic factors. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 723-729.	3.3	44
146	Whole Brain Irradiation With Hippocampal Sparing and Dose Escalation on Multiple Brain Metastases: A Planning Study on Treatment Concepts. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 264-270.	0.8	72
147	Combined Radio- and Chemotherapy for Non-Small Cell Lung Cancer: Systematic Review of Landmark Studies Based on Acquired Citations. <i>Frontiers in Oncology</i> , 2013, 3, 176.	2.8	10
148	Does Time between Imaging Diagnosis and Initiation of Radiotherapy Impact Survival after Whole-Brain Radiotherapy for Brain Metastases?. <i>ISRN Oncology</i> , 2013, 2013, 1-4.	2.1	2
149	Increasing frequency of reirradiation studies in radiation oncology: systematic review of highly cited articles. <i>American Journal of Cancer Research</i> , 2013, 3, 152-8.	1.4	11
150	Palliative radiotherapy in patients with metastatic non-small cell lung cancer. <i>Annals of Palliative Medicine</i> , 2013, 2, 51-3.	1.2	3
151	A Case of Brain Metastases from Breast Cancer Treated with Whole-Brain Radiotherapy and Eribulin Mesylate. <i>Case Reports in Oncological Medicine</i> , 2012, 2012, 1-3.	0.3	7
152	Ipilimumab in patients with melanoma and brain metastases. <i>Lancet Oncology</i> , The, 2012, 13, e277.	10.7	6
153	Contribution of case reports to glioblastoma research: Systematic review and analysis of pattern of citation. <i>British Journal of Neurosurgery</i> , 2012, 26, 809-812.	0.8	6
154	Brain metastases in patients under 50 years of age: retrospective analysis. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 949-956.	3.3	5
155	Adding cetuximab to stereotactic radiotherapy for non-small cell lung cancer might reduce local failure rates. <i>Medical Hypotheses</i> , 2012, 78, 420-422.	1.5	3
156	Glioblastoma research 2006–2010: Pattern of citation and systematic review of highly cited articles. <i>Clinical Neurology and Neurosurgery</i> , 2012, 114, 1207-1210.	1.4	12
157	Non-small cell lung cancer histological subtype has prognostic impact in patients with brain metastases. <i>Medical Oncology</i> , 2012, 29, 2664-2668.	2.5	8
158	Towards Improved Prognostic Scores Predicting Survival in Patients with Brain Metastases: A Pilot Study of Serum Lactate Dehydrogenase Levels. <i>Scientific World Journal</i> , The, 2012, 2012, 1-5.	2.1	12
159	Socioeconomic characteristics and health outcomes in Sami speaking municipalities and a control group in northern Norway. <i>International Journal of Circumpolar Health</i> , 2012, 71, 19127.	1.2	11
160	Brain Metastases Research 1990–2010: Pattern of Citation and Systematic Review of Highly Cited Articles. <i>Scientific World Journal</i> , The, 2012, 2012, 1-9.	2.1	7
161	A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer. <i>Radiation Oncology</i> , 2012, 7, 3.	2.7	22
162	Use of the Graded Prognostic Assessment (GPA) score in patients with brain metastases from primary tumours not represented in the diagnosis-specific GPA studies. <i>Strahlentherapie Und Onkologie</i> , 2012, 188, 692-695.	2.0	26

#	ARTICLE	IF	CITATIONS
163	Diagnosis-specific graded prognostic assessment score is valid in patients with brain metastases treated in routine clinical practice in two European countries. <i>Medical Science Monitor</i> , 2012, 18, CR450-CR455.	1.1	26
164	Contribution of Case Reports to Brain Metastases Research: Systematic Review and Analysis of Pattern of Citation. <i>PLoS ONE</i> , 2012, 7, e34300.	2.5	3
165	A population-based study of the pattern of terminal care and hospital death in patients with non-small cell lung cancer. <i>Anticancer Research</i> , 2012, 32, 189-94.	1.1	12
166	Early palliative care in patients with metastatic non-small cell lung cancer. <i>Annals of Palliative Medicine</i> , 2012, 1, 84-6.	1.2	8
167	Postoperative treatment and prognosis of patients with resected single brain metastasis: How useful are established prognostic scores?. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 98-103.	1.4	15
168	Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma. <i>Medical Hypotheses</i> , 2011, 76, 410-413.	1.5	15
169	Treatment of brain metastases from renal cell cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 405-410.	1.6	29
170	Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: Patterns of failure. <i>Radiotherapy and Oncology</i> , 2011, 101, 245-249.	0.6	106
171	Comorbidity, Use of Common Medications, and Risk of Early Death in Patients with Localized or Locally Advanced Prostate Cancer. <i>Scientific World Journal</i> , The, 2011, 11, 1178-1186.	2.1	10
172	Does overall treatment time impact on survival after whole-brain radiotherapy for brain metastases?. <i>Clinical and Translational Oncology</i> , 2011, 13, 885-888.	2.4	2
173	Presentation, patterns of care, and survival in patients with brain metastases. <i>Cancer</i> , 2011, 117, 2505-2512.	4.1	163
174	A Thought-Provoking Retrospective Study on Survival and Toxicity After Reirradiation for Recurrent High-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2011, 29, e121-e121.	1.6	1
175	Can current prognostic scores reliably guide treatment decisions in patients with brain metastases from malignant melanoma?. <i>Journal of Cancer Research and Therapeutics</i> , 2011, 7, 47.	0.9	21
176	Impact of common medications on serum total prostate-specific antigen levels and risk group assignment in patients with prostate cancer. <i>Anticancer Research</i> , 2011, 31, 1735-9.	1.1	2
177	Normal Tissue Tolerance to Reirradiation. <i>Medical Radiology</i> , 2010, , 1-12.	0.1	0
178	Fractionation Concepts. <i>Medical Radiology</i> , 2010, , 13-26.	0.1	0
179	Validation of New Prognostic and Predictive Scores by Sequential Testing Approach. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 169-173.	2.0	6
180	Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases. <i>BMC Cancer</i> , 2010, 10, 284.	2.6	41

#	ARTICLE	IF	CITATIONS
181	Estimating Need for Palliative External Beam Radiotherapy in Adult Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 207-211.	0.8	18
182	Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases. <i>BMC Urology</i> , 2010, 10, 23.	1.4	10
183	Brain Metastases. <i>Medical Radiology</i> , 2010, , 209-223.	0.1	0
184	Resource Utilization in Patients with Brain Metastases Managed with Best Supportive Care, Radiotherapy and/or Surgical Resection: A Markov Analysis. <i>Oncology</i> , 2010, 78, 348-355.	1.9	22
185	Leptomeningeal carcinomatosis from renal cell cancer: treatment attempt with radiation and sunitinib (case report). <i>World Journal of Surgical Oncology</i> , 2010, 8, 36.	1.9	13
186	A new prognostic score derived from phase I study participants with advanced solid tumours is also valid in patients with brain metastasis. <i>Anticancer Research</i> , 2010, 30, 977-9.	1.1	6
187	Colorectal Cancer Metastatic to the Brain: Time Trends in Presentation and Outcome. <i>Oncology</i> , 2009, 76, 369-374.	1.9	50
188	Validation of the graded prognostic assessment index for patients with brain metastases. <i>Acta Oncologica</i> , 2009, 48, 457-459.	1.8	30
189	Prognostic scores in brain metastases from breast cancer. <i>BMC Cancer</i> , 2009, 9, 105.	2.6	40
190	Presentation and outcome in cancer patients with extensive spread to the brain. <i>BMC Research Notes</i> , 2009, 2, 247.	1.4	3
191	Prognostic indices for brain metastases – usefulness and challenges. <i>Radiation Oncology</i> , 2009, 4, 10.	2.7	91
192	Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Non-Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1069-1076.	0.8	161
193	Prognostic Scores in Patients with Brain Metastases from Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1337-1341.	1.1	41
194	Quantitative Cell Kill of Radio- and Chemotherapy. <i>Medical Radiology</i> , 2009, , 169-190.	0.1	1
195	Mechanisms of Treatment Resistance: Molecular and Clinical Examples for Radio- and Chemotherapy. <i>Medical Radiology</i> , 2009, , 243-250.	0.1	0
196	Dose-Escalated High-Precision Radiotherapy: a Method to Overcome Variations in Biology and Radiosensitivity Limiting the Success of Conventional Approaches?. <i>Medical Radiology</i> , 2009, , 335-346.	0.1	0
197	Does distance to treatment centre influence the rate of palliative radiotherapy in adult cancer patients?. <i>Anticancer Research</i> , 2009, 29, 2641-4.	1.1	12
198	Effects of Smoking Cessation on Hypoxia and its Potential Impact on Radiation Treatment Effects in Lung Cancer Patients. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 605-609.	2.0	16

#	ARTICLE	IF	CITATIONS
199	Two New Prognostic Indices for Brain Metastases – Where Do We Go from Here?. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 488-489.	2.0	3
200	Can prophylactic breast irradiation contribute to cardiac toxicity in patients with prostate cancer receiving androgen suppressing drugs?. <i>Radiation Oncology</i> , 2008, 3, 2.	2.7	6
201	Validation of Graded Prognostic Assessment Index for Patients With Brain Metastases: In Regard to Sperduto et al. (<i>Int J Radiat Oncol Biol Phys</i> 2008;70:510–514). <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1619.	0.8	10
202	Disease Presentation and Treatment Outcome in Very Young Patients with Brain Metastases from Lung Cancer. <i>Onkologie</i> , 2008, 31, 305-308.	0.8	5
203	Improvement, Clinical Course, and Quality of Life After Palliative Radiotherapy for Recurrent Glioblastoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 300-305.	1.3	94
204	Presentation and course of brain metastases from breast cancer in a paranoid-schizophrenic patient: A case report. <i>Cases Journal</i> , 2008, 1, 195.	0.4	0
205	Have Changes in Systemic Treatment Improved Survival in Patients with Breast Cancer Metastatic to the Brain?. <i>Journal of Oncology</i> , 2008, 2008, 1-5.	1.3	3
206	Disease presentation and outcome in young patients (<40 years) with brain metastases from malignant melanoma. <i>Anticancer Research</i> , 2008, 28, 1325-7.	1.1	6
207	Validation of the graded prognostic assessment index for surgically treated patients with brain metastases. <i>Anticancer Research</i> , 2008, 28, 3015-7.	1.1	16
208	Disease presentation and outcome in very young patients with brain metastases from breast cancer. <i>Tumori</i> , 2008, 94, 691-3.	1.1	0
209	Is Whole-Brain Radiotherapy Effective and Safe in Elderly Patients with Brain Metastases?. <i>Oncology</i> , 2007, 72, 326-329.	1.9	13
210	Radiation Therapy Plus Angiogenesis Inhibition with Bevacizumab: Rationale and Initial Experience. <i>Reviews on Recent Clinical Trials</i> , 2007, 2, 163-168.	0.8	23
211	Comparison of three different mediastinal radiotherapy techniques in female patients: Impact on heart sparing and dose to the breasts. <i>Radiotherapy and Oncology</i> , 2007, 82, 301-307.	0.6	41
212	An uncommon presentation and course of metastatic malignant melanoma: a case report. <i>Journal of Medical Case Reports</i> , 2007, 1, 151.	0.8	1
213	What Approach will Lead to Cure of Glioblastoma Multiforme?: In Regard to Barani et al. (<i>Int J Radiat Oncol Biol Phys</i>) Tj ETQq1 1 0.784314 rgBT /Overlock 10 <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 640-641.	0.8	2
214	Re-Irradiation for Recurrent Head and Neck Cancer: in Regard to Lee et al. (<i>Int J Radiat Oncol Biol Phys</i>) Tj ETQq0 0.0 rgBT /Overlock 10	0.8	3
215	Influence of different treatment techniques on radiation dose to the LAD coronary artery. <i>Radiation Oncology</i> , 2007, 2, 20.	2.7	38
216	Experimental concepts for toxicity prevention and tissue restoration after central nervous system irradiation. <i>Radiation Oncology</i> , 2007, 2, 23.	2.7	19

#	ARTICLE	IF	CITATIONS
217	The Role of Postoperative Radiotherapy after Resection of a Single Brain Metastasis. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 576-580.	2.0	48
218	Evaluation of insulin-like growth factor-1 in a mouse model of long-term abdominal radiation toxicity. <i>Anticancer Research</i> , 2007, 27, 183-7.	1.1	0
219	Evaluation of late neurologic adverse events in patients with brain metastases from non-small cell lung cancer. <i>Anticancer Research</i> , 2007, 27, 1701-4.	1.1	3
220	Analysis of long-term survivors of glioblastoma multiforme in a single institution with aggressive local retreatment protocol. <i>Anticancer Research</i> , 2007, 27, 2993-6.	1.1	6
221	Detrimental effects of an antibody directed against tumor necrosis factor alpha in experimental kidney irradiation. <i>Anticancer Research</i> , 2007, 27, 2353-7.	1.1	3
222	Current status of angiogenesis inhibitors combined with radiation therapy. <i>Cancer Treatment Reviews</i> , 2006, 32, 348-364.	7.7	109
223	Combined Modality Treatment of Glioblastoma Multiforme: The Role of Temozolomide. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 43-51.	0.8	19
224	Integration of chemotherapy into current treatment strategies for brain metastases from solid tumors. <i>Radiation Oncology</i> , 2006, 1, 19.	2.7	15
225	Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 181-193.	4.4	97
226	Dose to the intracranial arteries in stereotactic and intensity-modulated radiotherapy for skull base tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1055-1059.	0.8	6
227	Preclinical evaluation of erythropoietin administration in a model of radiation-induced kidney dysfunction. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1513-1518.	0.8	12
228	¹¹ C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 339-344.	0.8	97
229	Update of human spinal cord reirradiation tolerance based on additional data from 38 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1446-1449.	0.8	198
230	Stereotactic Fractionated Radiotherapy for Recurrent Capillary Hemangioma of the Cavernous Sinus. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 179-182.	2.0	27
231	High-Precision Radiation Therapy with Integrated Biological Imaging and Tumor Monitoring. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 361-368.	2.0	29
232	Acceleration of Normal-Tissue Damage Expression by Early Stimulation of Cell Proliferation in Rat Spinal Cord. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 680-684.	2.0	6
233	Applications in Malignant Brain Tumors. , 2006, , 165-186.		1
234	Early and Late Treatment-Induced Toxicity. , 2006, , 317-332.		3

#	ARTICLE	IF	CITATIONS
235	L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 64-74.	0.8	236
236	Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 511-519.	0.8	351
237	Potential Role of Growth Factors in Diminishing Radiation Therapy Neural Tissue Injury. <i>Seminars in Oncology</i> , 2005, 32, 67-70.	2.2	15
238	Radiotherapy and Chemotherapy for Myoepithelioma of the Sellar Region. <i>Strahlentherapie Und Onkologie</i> , 2005, 181, 260-263.	2.0	20
239	Effects of Insulin-Like Growth Factor-1 (IGF-1) and Amifostine in Spinal Cord Reirradiation. <i>Strahlentherapie Und Onkologie</i> , 2005, 181, 691-695.	2.0	17
240	Proposal of human spinal cord reirradiation dose based on collection of data from 40 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 851-855.	0.8	146
241	Effects of radiotherapy and chemotherapy on sensory deficits from spinal cord damage. <i>Acta Oncologica</i> , 2005, 44, 412-414.	1.8	1
242	Response Monitoring by Positron Emission Tomography during Radiotherapy of a Squamous Cell Skin Carcinoma. <i>Oncology Research and Treatment</i> , 2005, 28, 505-507.	1.2	1
243	Evaluation of insulin-like growth factor-1 for prevention of radiation-induced spinal cord damage. <i>Growth Factors</i> , 2005, 23, 15-18.	1.7	9
244	The role of pentoxifylline as a modifier of radiation therapy. <i>Cancer Treatment Reviews</i> , 2005, 31, 448-455.	7.7	42
245	Treatment of unresectable glioblastoma multiforme. <i>Anticancer Research</i> , 2005, 25, 4605-10.	1.1	36
246	Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 691-703.	2.8	18
247	Radiotherapy for High-Grade Gliomas. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 401-407.	2.0	90
248	Modulation of rodent spinal cord radiation tolerance by administration of platelet-derived growth factor. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1257-1263.	0.8	16
249	Clinical effectiveness of radiotherapy for non-Hodgkin's lymphoma: a summary. <i>Cancer Treatment Reviews</i> , 2004, 30, 221-224.	7.7	0
250	Brain Metastases in Renal Cell Cancer: Diagnostic and Therapeutic Aspects. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 632-634.	1.3	3
251	Prevention of radiation-induced central nervous system toxicity: a role for amifostine?. <i>Anticancer Research</i> , 2004, 24, 3803-9.	1.1	20
252	Recursive Partitioning Analysis (RPA) Class Does Not Predict Survival in Patients with Four or More Brain Metastases. <i>Strahlentherapie Und Onkologie</i> , 2003, 179, 16-20.	2.0	51

#	ARTICLE	IF	CITATIONS
253	Influence of differing radiotherapy strategies on treatment results in diffuse large-cell lymphoma: a review. <i>Cancer Treatment Reviews</i> , 2003, 29, 11-19.	7.7	21
254	The role of growth factors in central nervous system tumours. <i>Anticancer Research</i> , 2003, 23, 1681-6.	1.1	13
255	Radiotherapy-induced lung toxicity: risk factors and prevention strategies. <i>Anticancer Research</i> , 2003, 23, 4991-8.	1.1	15
256	Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. <i>Anticancer Research</i> , 2003, 23, 5117-23.	1.1	20
257	Cervical lymph node metastases from occult squamous cell carcinoma. <i>Current Treatment Options in Oncology</i> , 2002, 3, 33-40.	3.0	25
258	Retreatment of the spinal cord with palliative radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 1288-1292.	0.8	54
259	Innovative prevention strategies for radiation necrosis of the central nervous system. <i>Anticancer Research</i> , 2002, 22, 1017-23.	1.1	16
260	Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 727-733.	0.8	170
261	A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer VS. conventionally fractionated 60 GY: results of a randomized equivalence study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 95-103.	0.8	87
262	Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 46, 297-302.	0.8	165
263	Tissue tolerance to reirradiation. <i>Seminars in Radiation Oncology</i> , 2000, 10, 200-209.	2.2	175
264	A Review of Current and Future Treatment Strategies for Malignant Astrocytomas in Adults. <i>Strahlentherapie Und Onkologie</i> , 2000, 176, 251-258.	2.0	26
265	Dose-Response Relationships for Radiotherapy of Brain Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000, 23, 584-588.	1.3	8
266	Hypofractionated Stereotactic Radiotherapy for Malignant Glioma: A Phase I/II Study. <i>Journal of Radiosurgery</i> , 1999, 2, 107-111.	0.1	9
267	Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. , 1999, 85, 251-252.		8
268	Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma. , 1999, 86, 900-902.		74
269	Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme. <i>Radiation Oncology Investigations</i> , 1999, 7, 36-41.	0.9	23
270	Radiation myelopathy: New perspective on an old problem. <i>Radiation Oncology Investigations</i> , 1999, 7, 193-203.	0.9	18

#	ARTICLE	IF	CITATIONS
271	Hyperfractionated and accelerated hyperfractionated radiotherapy for glioblastoma multiforme. Radiation Oncology Investigations, 1999, 7, 36-41.	0.9	3
272	Late Radiation Toxicity After Whole-Brain Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 573.	1.3	76
273	Dose/effect relationships for brain metastases. Journal of Cancer Research and Clinical Oncology, 1998, 124, 346-350.	2.5	36
274	Patterns of relapse and late toxicity after resection and whole-brain radiotherapy for solitary brain metastases. Strahlentherapie Und Onkologie, 1998, 174, 275-278.	2.0	60
275	Multivariate logistic analysis of dose-effect relationship and latency of radiomyelopathy after hyperfractionated and conventionally fractionated radiotherapy in animal experiments. International Journal of Radiation Oncology Biology Physics, 1998, 41, 681-688.	0.8	14
276	Accelerated radiotherapy for brain metastases. Radiotherapy and Oncology, 1997, 45, 17-22.	0.6	24
277	Tumor-related prognostic factors for remission of brain metastases after radiotherapy. International Journal of Radiation Oncology Biology Physics, 1997, 39, 25-30.	0.8	117
278	Rapid course radiation therapy vs. more standard treatment: A randomized trial for bone metastases. International Journal of Radiation Oncology Biology Physics, 1996, 36, 1085-1089.	0.8	129
279	Relation between local result and total dose of radiotherapy for brain metastases. International Journal of Radiation Oncology Biology Physics, 1995, 33, 349-355.	0.8	60
280	Randomized Controlled Clinical Trials in Radiation Therapy: Patterns of Publication in the Most Frequently Cited Studies. Medical Science Review, 0, 2, 104-110.	0.0	0